中重度创伤性脑损伤患者血清生物标志物与临床影像学评估的相关性
这项前瞻性单中心研究纳入2019年11月5日至2020年11月4日尼日利亚阿布贾国家医院收治的44例中重度创伤性脑损伤(TBI)患者,于入院时及伤后3天、7天检测血清GFAP、NSE和S100β蛋白,并在伤后3个月用格拉斯哥结局量表评估结局。结果显示上述标志物入院时均高于正常参考值,重度TBI患者显著高于中度TBI患者(p<0.05),生物标志物水平与格拉斯哥昏迷量表评分呈负相关,结局不良者标志物水平更高;GFAP的AUC最高,为0.828。
要点
- 入院时GFAP、NSE、S100β蛋白均值分别为1.85±1.12 ng/ml、14.25±2.77 ng/ml、0.60±0.20 ng/ml,均高于正常参考值。
- 重度TBI患者血清GFAP、NSE、S100β蛋白水平显著高于中度TBI患者(p<0.05)。
- GFAP对中重度TBI结局的预测AUC最高,为0.828,高于NSE的0.759和S100β蛋白的0.750。
核心结论
- 在所研究的标志物中,S100β蛋白与影像学表现的相关性最优,而GFAP对中重度TBI患者结局的预测能力最可靠。
研究设计与样本
- 前瞻性单中心研究,纳入2019年11月5日至2020年11月4日尼日利亚阿布贾国家医院收治的44例中重度TBI患者。
- 于入院时及伤后3天、7天用酶联免疫吸附试验试剂盒检测血清GFAP、NSE和S100β蛋白,伤后3个月用格拉斯哥结局量表评估结局。
主要发现
- 入院时GFAP均值1.85±1.12 ng/ml、NSE均值14.25±2.77 ng/ml、S100β蛋白均值0.60±0.20 ng/ml,均高于正常参考值。
- 重度TBI患者血清GFAP、NSE、S100β蛋白水平显著高于中度TBI患者(p<0.05)。
- 血清生物标志物水平与格拉斯哥昏迷量表评分呈负相关,结局不良患者生物标志物水平更高。
- 入院24小时内GFAP和NSE与Rotterdam CT评分呈负相关,而S100β蛋白与Rotterdam CT评分呈正相关。
- GFAP的AUC最高,为0.828,NSE为0.759,S100β蛋白为0.750。
关键数值与推荐
- 重度TBI与中度TBI患者血清GFAP、NSE、S100β蛋白水平比较,p<0.05。
- GFAP预测结局的AUC为0.828,NSE为0.759,S100β蛋白为0.750。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Despite advancements in traumatic brain injury (TBI) management and the development of standardized care guidelines, mortality and morbidity rates remain high. Current diagnostic and prognostic tools are limited, particularly in resource-constrained settings. This study investigated the potential role of serum biomarkers, including glial fibrillary acidic protein (GFAP), neuron-specific enolase (NSE), and S100β protein, in assessing the clinical severity and outcomes of patients with moderate and severe TBI in a Nigerian trauma center. METHODS: This prospective, single-center study included 44 patients with moderate and severe TBI admitted to the National Hospital Abuja, Nigeria, from November 5, 2019, to November 4, 2020. Clinical and radiological data were documented, and serum levels of GFAP, NSE, and S100β protein were measured at admission, as well as 3 and 7 days postinjury, using enzyme-linked immunosorbent assay kits. Treatment outcomes were assessed using the Glasgow Outcome Scale at 3 months post-TBI. RESULTS: At admission, mean serum levels of GFAP (1.85 ± 1.12 ng/ml), NSE (14.25 ± 2.77 ng/ml), and S100β protein (0.60 ± 0.20 ng/ml) were elevated beyond normal reference values. Serum levels were significantly higher in patients with severe TBI compared with those with moderate TBI (p < 0.05). An inverse relationship was observed between serum biomarker levels and Glasgow Coma Scale scores, with patients experiencing unfavorable outcomes exhibiting higher biomarker levels. Additionally, GFAP and NSE showed an inverse correlation with the Rotterdam CT score within 24 hours of admission, while S100β protein demonstrated a direct correlation. The area under the curve for GFAP was the highest at 0.828, compared with 0.759 for NSE and 0.750 for S100β protein. CONCLUSIONS: Among the biomarkers studied, S100β protein showed a superior correlation with radiological findings, whereas GFAP demonstrated the most reliable predictive ability for prognosticating outcomes in patients with moderate and severe TBI.
引用
- Adebiyi JA, Yusuf AS, Mahmud MR, et al. Correlation of serum biomarkers with clinicoradiological assessments in patients with moderate and severe traumatic brain injury. J Neurosurg. 2025. PMID: 40378480. doi:10.3171/2025.1.JNS242182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。